Results of surgical treatment of non–small cell lung cancer: validation of the new postoperative pathologic tnm classification Jacek Jassem, MDa, Jan.

Slides:

Advertisements

Similar presentations

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Advertisements

Stephen R. Broderick, MD, MPHS

A novel test of the surgical margin in patients with lung cancer undergoing limited surgery: Lavage cytologic technique Masahiko Higashiyama, MDa, Ken.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients

Intraoperative lavage cytologic analysis of surgical margins in patients undergoing limited surgery for lung cancer Masahiko Higashiyama, MDa, Ken Kodama,

Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Detection of circulating tumor cells in patients with non–small cell lung cancer undergoing lobectomy by video-assisted thoracic surgery: A potential.

Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience Tsuguo Naruke,

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer Walter Weder, MD, Stéphane Collaud, MD,

Lobe-specific extent of systematic lymph node dissection for non–small cell lung carcinomas according to a retrospective study of metastasis and prognosis

Iwao Takanami, MD, Ken Takeuchi, MD, Masatoshi Giga, MD

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Rodney J. Landreneau, MDa, David J. Sugarbaker, MDb, Michael J

Refining esophageal cancer staging

Preoperative evidence of circulating tumor cells by means of reverse transcriptase- polymerase chain reaction for carcinoembryonic antigen messenger RNA.

Stage III non–small cell lung cancer and metachronous brain metastases

A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer.

Management of patients with intramural hematoma involving the ascending aorta Yoshimasa Moizumi, MDa, Tsunehiro Komatsu, MDa, Naotaka Motoyoshi, MDa,

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Is tissue the issue? Brian E. Louie, MD, MHA, MPH, FRCSC, FACS

Yang Zhang, MD, Haiquan Chen, MD, PhD

Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: A predictor of lymph node metastasis

Large cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighty- seven cases Hidefumi Takei, MDa,b, Hisao Asamura, MDb, Arafumi Maeshima,

Occult active giant cell aortitis necessitating surgical repair

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Support Your Specialty

Aggressive management of lung donors classified as unacceptable: Excellent recipient survival one year after transplantation Michaela Straznicka, MDa,

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

Ruptured bronchial artery aneurysm associated with sarcoidosis

Prognostic assessment of 1310 patients with non–small-cell lung cancer who underwent complete resection from 1980 to 1993 Kunihiko Inoue, MDa, Masami.

Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective Gaetano Rocco, MD, Katie Nason, MD, MPH, Alex Brunelli, MD, Gonzalo.

Pulmonary metabolism of endothelin 1 during on-pump and beating heart coronary artery bypass operations Patrick Mathieu, MDa, Jocelyn Dupuis, MD, PhDb,

Stephen R. Broderick, MD, MPHS

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results Manjit S. Bains, MDa, Alexander Stojadinovic,

Frederick L. Grover, MDa, b, David J

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Tuberculous aneurysm of the descending thoracic aorta

Lymph Node Metastasis In Small Peripheral Adenocarcinoma Of The Lung

Victor O. Morell, MDa, Jeffrey P. Jacobs, MDb, James A

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Body weight and nutritional changes after reduction pneumoplasty for severe emphysema: A randomized study Tommaso Claudio Mineo, MDa, Vincenzo Ambrogi,

Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non–small cell lung cancer Dominique H. Grunenwald, MDa, Fabrice André, MDb,

O. S. Breathnach, MDa, D. J. Kwiatkowski, MD, PhDb, D. M

Problems related to TNM staging: Patients with stage III non–small cell lung cancer Kotaro Kameyama, MD, Cheng-long Huang, MD, Dage Liu, MD, Taku Okamoto,

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Bilobectomy for massive hemoptysis after bilateral lung transplantation Stefan Guth, MDa, Eckhard Mayer, MDa, Berthold Fischer, MDb, Jana Lill, MDb, Norbert.

Superior sulcus lung tumors: Impact of local control on survival

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Tai Ji: The law of inflammatory response

Second operation for upper mediastinal lymphadenopathy after complete resection for cancer of the left lung Masami Sato, MDa, b, Teruaki Koike, MDa,

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Building a clinical program in a single institution

Aritoshi Hattori, MD, Kenji Suzuki, MD

Prognostic factors and long-term results after thymoma resection: A series of 307 patients Jean-François Regnard, MDa, Pierre Magdeleinat, MDa, Christian.

Who should decide margin length in pulmonary excision of lung cancer?

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung.

Nael Martini, MDa, Valerie W. Rusch, MDa, Manjit S. Bains, MDa, Mark G

Pulmonary transplantation for advanced bronchioloalveolar carcinoma

Proceed with caution: The importance of surveillance in patients with pathologic complete response after chemoradiation therapy plus surgery for esophageal.

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Presentation transcript:

Results of surgical treatment of non–small cell lung cancer: validation of the new postoperative pathologic tnm classification Jacek Jassem, MDa, Jan Skokowski, MDb, Rafał Dziadziuszko, MDa, Ewa Jassem, MDc, Amelia Szymanowska, BScc, Witold Rzyman, MDb, Andrzej Roszkiewicz, MDd The Journal of Thoracic and Cardiovascular Surgery Volume 119, Issue 6, Pages 1141-1146 (June 2000) DOI: 10.1067/mtc.2000.105825 Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

Fig. 1 Probability of survival according to clinical stage. Stage IIA is not presented because of a limited number of patients. The Journal of Thoracic and Cardiovascular Surgery 2000 119, 1141-1146DOI: (10.1067/mtc.2000.105825) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

Fig. 2 Probability of survival in the T3 N0 category (n = 55) and stage IIIA (n = 154; T3 N0 vs IIIA: P = .03 and P = .02 for Wilcoxon and log-rank test, respectively). The Journal of Thoracic and Cardiovascular Surgery 2000 119, 1141-1146DOI: (10.1067/mtc.2000.105825) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

Fig. 3 Probability of survival in stage IIIA subcategories: T3 N1 (n = 26), T1-2 N2 (n = 95), and T3 N2 (n = 33). The Journal of Thoracic and Cardiovascular Surgery 2000 119, 1141-1146DOI: (10.1067/mtc.2000.105825) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions